{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464215377
| IUPAC_name = 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine
| image = Proguanil.svg

<!--Clinical data-->
| synonyms = chlorguanide, chloroguanide<ref>{{cite book|last1=Mehlhorn|first1=Heinz|title=Encyclopedia of Parasitology: A-M|date=2008|publisher=Springer Science & Business Media|isbn=9783540489948|page=388|url=https://books.google.ca/books?id=Jpg1ysgVn-AC&pg=PA388|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20161220074710/https://books.google.ca/books?id=Jpg1ysgVn-AC&pg=PA388|archivedate=2016-12-20|df=}}</ref>
| tradename = Paludrine, others
| Drugs.com = {{drugs.com|CONS|proguanil}}
| pregnancy_category =  
| legal_status = ℞-only
| routes_of_administration = By [[mouth]] ([[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 75%
| metabolism = By [[liver]] ([[CYP2C19]]) 
| elimination_half-life = 12–21 hours<ref>{{cite web|title=Malarone (atovaquone/proguanil) Tablets, Pediatric Tablets. Full Prescribing Information|url=https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Malarone/pdf/MALARONE.PDF|publisher=GlaxoSmithKline. Research Triangle Park, NC 27709|accessdate=14 July 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160920173748/https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Malarone/pdf/MALARONE.PDF|archivedate=20 September 2016|df=}}</ref>
| metabolites = [[cycloguanil]] and 4-chlorophenylbiguanide

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 500-92-5
| ATC_prefix = P01
| ATC_suffix = BB01
| PubChem = 4923
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01131
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4754
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S61K3P7B2V
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08428
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8455
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1377

<!--Chemical data-->
| C=11 | H=16 | Cl=1 | N=5
| molecular_weight = 253.731 g/mol
| SMILES = Clc1ccc(NC(=N/C(=N/C(C)C)N)N)cc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SSOLNOMRVKKSON-UHFFFAOYSA-N
| melting_point = 129
}}

<!-- Definition and medical uses -->
'''Proguanil''', also known as '''chlorguanide''' and '''chloroguanide''', is a medication used to treat and prevent [[malaria]].<ref name=WHO2008/><ref name=AHFS2016/> It is often used together with [[chloroquine]] or [[atovaquone]].<ref name=AHFS2016/><ref name=WHO2008>{{cite book|title=WHO Model Formulary 2008|date=2009|publisher=World Health Organization|isbn=9789241547659|pages=199, 203, 594|url=http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161213060118/http://apps.who.int/medicinedocs/documents/s16879e/s16879e.pdf|archivedate=13 December 2016|df=}}</ref> When used with chloroquine the combination will treat mild chloroquine resistant malaria.<ref name=WHO2008/> It is taken by mouth.<ref name=ERC2014/>

<!-- Side effects and mechanism -->
Side effects include diarrhea, constipation, skin rashes, hair loss, and itchiness.<ref name=WHO2008/> Because malaria tends to be more severe in [[pregnancy]], the benefit typically outweighs the risk.<ref name=WHO2008/> If used during pregnancy it should be taken with [[folate]].<ref name=WHO2008/> It is likely safe for use during [[breastfeeding]].<ref name=WHO2008/> Proguanil is converted by the liver to its active metabolite, [[cycloguanil]].<ref name=AHFS2016>{{cite web|title=Atovaquone and Proguanil Hydrochloride|url=https://www.drugs.com/monograph/atovaquone-and-proguanil-hydrochloride.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220223925/https://www.drugs.com/monograph/atovaquone-and-proguanil-hydrochloride.html|archivedate=20 December 2016|df=}}</ref>

<!-- History and culture -->
Proguanil has been studied at least since 1945.<ref>{{Cite journal|last=Nzila|first=Alexis|date=2006-06-01|title=The past, present and future of antifolates in the treatment of Plasmodium falciparum infection|url=http://jac.oxfordjournals.org/content/57/6/1043|journal=Journal of Antimicrobial Chemotherapy|language=en|volume=57|issue=6|pages=1043–1054|doi=10.1093/jac/dkl104|issn=0305-7453|pmid=16617066}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> The wholesale cost in the [[developing world]] is about 0.10 to 0.50 USD per day.<ref name=ERC2014>{{cite web|title=Proguanil|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=PRG100T&s_year=2014&year=2014&str=100%20mg&desc=Proguanil&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E5%2E3%2E2&supplement=&class_name=%2806%2E5%2E3%2E2%29Antimalarial%20medicines%2C%20for%20prophylaxis%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United States and Canada it is only available in combination as [[atovaquone/proguanil]].<ref>{{Cite web|url=http://reference.medscape.com/drug/paludrine-proguanil-342692|title=Proguanil|last=|first=|date=|website=www.medscape.com|publisher=Medscape|access-date=8 November 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161109152802/http://reference.medscape.com/drug/paludrine-proguanil-342692|archivedate=9 November 2016|df=}}</ref>

==Medical uses==
Proguanil is used for the prevention and treatment of malaria in both adults and children, particularly in areas where [[chloroquine]]-resistant [[Plasmodium falciparum|''P. falciparum'']] malaria has been reported. It is usually taken in combination with [[atovaquone]], another antimalarial drug.<ref>{{Cite web|url=https://medlineplus.gov/ency/article/000621.htm|title=Malaria: MedlinePlus Medical Encyclopedia|website=medlineplus.gov|access-date=2016-11-16|deadurl=no|archiveurl=https://web.archive.org/web/20161117064956/https://medlineplus.gov/ency/article/000621.htm|archivedate=2016-11-17|df=}}</ref>

It is also effective in the treatment of most other multi-drug resistant forms of ''P. falciparum''; the success rate exceeds 93%.<ref>{{Cite journal|last=Boggild|first=Andrea K.|last2=Parise|first2=Monica E.|last3=Lewis|first3=Linda S.|last4=Kain|first4=Kevin C.|date=2007-02-01|title=Atovaquone-Proguanil: Report from the Cdc Expert Meeting on Malaria Chemoprophylaxis (ii)|url=http://www.ajtmh.org/content/76/2/208|journal=The American Journal of Tropical Medicine and Hygiene|language=en|volume=76|issue=2|pages=208–223|issn=0002-9637|pmid=17297027}}</ref>

==Side effects==
Proguanil is generally well-tolerated and most people do not experience side effects. However, common side effects include abdominal pain, nausea, headache, and fever. Taking proguanil with food may lessen these side effects.<ref>{{Cite web|url=http://www.mayoclinic.org/drugs-supplements/atovaquone-and-proguanil-oral-route/side-effects/drg-20061484|title=Atovaquone And Proguanil (Oral Route) Side Effects - Mayo Clinic|website=www.mayoclinic.org|access-date=2016-11-08|deadurl=no|archiveurl=https://web.archive.org/web/20161109090547/http://www.mayoclinic.org/drugs-supplements/atovaquone-and-proguanil-oral-route/side-effects/drg-20061484|archivedate=2016-11-09|df=}}</ref> Proguanil should not be taken by people with severe renal impairment, pregnant women, or women who are breastfeeding children less than 5&nbsp;kg.<ref>{{Cite web|url=https://www.cdc.gov/malaria/travelers/drugs.html|title=CDC - Malaria - Travelers - Choosing a Drug to Prevent Malaria|last=Prevention|first=CDC - Centers for Disease Control and|website=www.cdc.gov|access-date=2016-11-08|deadurl=no|archiveurl=https://web.archive.org/web/20161113071230/http://www.cdc.gov/malaria/travelers/drugs.html|archivedate=2016-11-13|df=}}</ref> There have also been reports of increased levels of liver enzymes, which may remain high for up to 4 weeks after completion of treatment.<ref>{{Cite journal|last=Looareesuwan|first=S.|last2=Wilairatana|first2=P.|last3=Chalermarut|first3=K.|last4=Rattanapong|first4=Y.|last5=Canfield|first5=C. J.|last6=Hutchinson|first6=D. B.|date=1999-04-01|title=Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand|journal=The American Journal of Tropical Medicine and Hygiene|volume=60|issue=4|pages=526–532|issn=0002-9637|pmid=10348224}}</ref>

==Mechanism==
When used alone, proguanil functions as a [[prodrug]]. Its active metabolite, [[cycloguanil]], is an inhibitor of [[dihydrofolate reductase]] (DHFR).<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/proguanil#section=Top|title=proguanil {{!}} C11H16ClN5 - PubChem|last=Pubchem|website=pubchem.ncbi.nlm.nih.gov|access-date=2016-11-13|deadurl=no|archiveurl=https://web.archive.org/web/20161114165700/https://pubchem.ncbi.nlm.nih.gov/compound/proguanil#section=Top|archivedate=2016-11-14|df=}}</ref> Although both mammals and parasites produce DHFR, cycloguanil's inhibitory activity is specific for parasitic DHFR. This enzyme is a critical component of the folic acid cycle. Inhibition of DHFR prevents the parasite from recycling dihydrofolate back to [[Tetrahydrofolic acid|tetrahydrofolate]] (THF). THF is required for DNA synthesis, amino acid synthesis, and methylation; thus, DHFR inhibition shuts down these processes.<ref>{{Cite journal|last=Boggild|first=Andrea K.|last2=Parise|first2=Monica E.|last3=Lewis|first3=Linda S.|last4=Kain|first4=Kevin C.|date=2007-02-01|title=Atovaquone-Proguanil: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis (ii)|url=http://www.ajtmh.org/content/76/2/208|journal=The American Journal of Tropical Medicine and Hygiene|language=en|volume=76|issue=2|pages=208–223|issn=0002-9637|pmid=17297027}}</ref>

Proguanil displays [[synergy#Drug synergy|synergism]] when used in combination with the antimalarial atovaquone. This mechanism of action differs from when proguanil was used as a singular agent. In this case, it is not thought to function as a DHFR inhibitor. The addition of proguanil has shown to reduce resistance to atovaquone and increase the ability of atovaquone to trigger a mitochondrial apoptotic cascade.<ref>{{Cite journal|last=Srivastava|first=Indresh K.|last2=Vaidya|first2=Akhil B.|date=1999-06-01|title=A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil|journal=Antimicrobial Agents and Chemotherapy|volume=43|issue=6|pages=1334–1339|issn=0066-4804|pmc=89274|pmid=10348748}}</ref> This is commonly referred to as “collapse of the mitochondrial membrane potential.”<ref>{{Cite journal|last=Srivastava|first=Indresh K.|last2=Rottenberg|first2=Hagai|last3=Vaidya|first3=Akhil B.|date=1997-02-14|title=Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite|url=http://www.jbc.org/content/272/7/3961|journal=Journal of Biological Chemistry|language=en|volume=272|issue=7|pages=3961–3966|doi=10.1074/jbc.272.7.3961|issn=0021-9258|deadurl=no|archiveurl=https://web.archive.org/web/20141119004449/http://www.jbc.org/content/272/7/3961|archivedate=2014-11-19|df=}}</ref> Proguanil lowers the effective concentration of atovaquone needed to increase permeability of the mitochondrial membrane.<ref>{{cite journal | last1 = Thapar | first1 = MM | last2 = Gupta | first2 = S | last3 = Spindler | first3 = C | last4 = Wernsdorfer | first4 = WH | last5 = Björkman | first5 = A | title = Pharmacodynamic Interactions Among Atovaquone, Proguanil and Cycloguanil against ''Plasmodium falciparum'' ''in vitro'' | journal = Transactions of the Royal Society of Tropical Medicine and Hygiene | date = May 2003 | volume = 97 | issue = 3 | pages = 331–7 | doi = 10.1016/S0035-9203(03)90162-3 | pmid = 15228254  }}</ref>

==References==
{{reflist|32em}}

{{Antimalarials}}

[[Category:Antimalarial agents]]
[[Category:Biguanides]]
[[Category:Chloroarenes]]
[[Category:Prodrugs]]
[[Category:Protozoal dihydrofolate reductase inhibitors]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]